Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Mar 1:208:107877.
doi: 10.1016/j.drugalcdep.2020.107877. Epub 2020 Jan 22.

Enhancing panic and smoking reduction treatment with D-Cycloserine: A pilot randomized clinical trial

Jasper A J Smits  1 , Michael J Zvolensky  2 , Michael W Otto  3 , Megan E Piper  4 , Scarlett O Baird  5 , Brooke Y Kauffman  6 , Eunjung Lee-Furman  5 , Noura Alavi  5 , Christina D Dutcher  5 , Santiago Papini  5 , Benjamin Rosenfield  7 , David Rosenfield  8
Affiliations
Randomized Controlled Trial

Enhancing panic and smoking reduction treatment with D-Cycloserine: A pilot randomized clinical trial

Jasper A J Smits et al. Drug Alcohol Depend. .

Abstract

In this placebo-controlled randomized clinical trial, we examined the efficacy of 250 mg d-cycloserine (DCS) for enhancing the effects of cognitive behavior therapy targeting anxiety sensitivity reduction in the context of smoking cessation treatment among adults with a history of panic attacks. We hypothesized that DCS would enhance treatment of our mechanistic targets-anxiety sensitivity and panic and related symptoms-and result in greater smoking abstinence. A total of 53 smokers were randomized to a 7-week integrated treatment and received study medication (DCS or placebo) prior to sessions 3-5; these sessions emphasized interoceptive exposure practice. Nicotine replacement therapy was initiated at session 5 (quit date). We found that DCS augmentation led to greater reductions of one (anxiety sensitivity) of two of our mechanistic targets at early but not late assessments, and that engaging that target predicted better smoking outcomes. However, there was no evidence of group (DCS vs. placebo) differences in smoking cessation success at treatment endpoint or follow-up evaluations. Hence, although we found that DCS can enhance treatment targeting a smoking maintaining factor, additional strategies appear to be needed to significantly affect smoking outcomes.

Trial registration: ClinicalTrials.gov NCT01944423.

Keywords: Anxiety sensitivity; Behavioral intervention; Nicotine-Replacement therapy; Panic; Smoking cessation; d-cycloserine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Smits reports receiving support from the National Institutes of Health. He also receives compensation for his work as a consultant to Big Health and his work as editor for Elsevier and the American Psychological Association. He also receives royalties from various book publishers. Dr. Otto reports current and past support from National Institutes of Health. In addition, Dr. Otto reports serving, in the last three years, as a paid speaker and Scientific Advisory Board chair for Big Health, and receiving book royalties from Oxford University Press, Routledge, and Springer. Mr. Papini reports receiving support from the National Institutes of Health and the Donald D. Harrington Foundation.

Figures

Figure 1.
Figure 1.
CONSORT diagram
Figure 2.
Figure 2.
Model estimated ASI-3 score in the treatment and post-treatment phase
Figure 3.
Figure 3.
Model estimated PDSS-SR score in the treatment and post-treatment phase
Figure 4.
Figure 4.
Model estimated abstinence rate in the treatment and post-treatment phase.
Figure 5.
Figure 5.
Cross lag panel model for anxiety sensitivity and panic and related symptoms predicting abstinence at the next assessment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abrams K, Zvolensky MJ, Dorman L, Gonzalez A, Mayer M, 2011. Development and validation of the smoking abstinence expectancies questionnaire. Nicotine Tob. Res 13, 1296–1304. 10.1093/ntr/ntr184 - DOI - PubMed
    1. Asmundson GJG, Taylor S, Smits JAJ, 2014. Panic disorder and agoraphobia: an overview and commentary on DSM-5 changes. Depress. Anxiety 31, 480–486. 10.1002/da.22277 - DOI - PubMed
    1. Assayag Y, Bernstein A, Zvolensky MJ, Steeves D, Stewart SS, 2012. Nature and role of change in anxiety sensitivity during NRT-aided cognitive-behavioral smoking cessation treatment. Cogn. Behav. Ther 41, 51–62. 10.1080/16506073.2011.632437 - DOI - PubMed
    1. Bakhshaie J, Kulesz PA, Garey L, Langdon KJ, Businelle MS, Leventhal AM, Gallagher MW, Schmidt NB, Manning K, Goodwin R, Zvolensky MJ, 2018. A prospective investigation of the synergistic effect of change in anxiety sensitivity and dysphoria on tobacco withdrawal. J. Consult. Clin. Psychol 86, 69–80. 10.1037/ccp0000256 - DOI - PMC - PubMed
    1. Bakhshaie J, Zvolensky MJ, Langdon KJ, Leventhal AM, Smits JAJ, Allan N, Schmidt NB, 2016. Anxiety sensitivity class membership moderates the effects of pre-quit reduction in anxiety sensitivity on quit-day tobacco craving. J. Anxiety Disord. 39, 79–87. 10.1016/j.janxdis.2016.02.009 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data